Here are the latest quarterly results of Divis Laboratories. For more details, see the Divis Laboratories financial fact sheet and Divis Laboratories share price and chart. For a sector overview, read our pharmaceuticals sector report.
No. of Mths Qtr. Ending |
3
Sep-18 |
3
Dec-18 |
3
Mar-19 |
3
Jun-19 |
3
Sep-19 |
3
Dec-19 |
3
Mar-20 |
3
Jun-20 |
8-Qtr Chart Click to enlarge |
|
---|---|---|---|---|---|---|---|---|---|---|
Net Sales | Rs m | 12,850 | 13,429 | 12,564 | 11,399 | 14,456 | 13,905 | 13,762 | 17,100 | |
Other income | Rs m | 801 | 346 | 417 | 316 | 470 | 403 | 765 | 179 | |
Turnover | Rs m | 13,651 | 13,775 | 12,982 | 11,716 | 14,926 | 14,308 | 14,528 | 17,278 | |
Expenses | Rs m | 7,709 | 8,196 | 8,453 | 7,613 | 9,550 | 8,936 | 9,276 | 10,110 | |
Gross profit | Rs m | 5,141 | 5,233 | 4,111 | 3,786 | 4,906 | 4,969 | 4,486 | 6,990 | |
Depreciation | Rs m | 424 | 425 | 423 | 438 | 459 | 467 | 495 | 560 | |
Interest | Rs m | 2 | 25 | 1 | 3 | 38 | 16 | 4 | 2 | |
Profit before tax | Rs m | 5,516 | 5,129 | 4,104 | 3,661 | 4,879 | 4,889 | 4,752 | 6,607 | |
Tax | Rs m | 1,539 | 1,334 | 1,210 | 988 | 1,311 | 1,282 | 834 | 1,685 | |
Profit after tax | Rs m | 3,977 | 3,795 | 2,894 | 2,674 | 3,568 | 3,607 | 3,918 | 4,923 | |
Gross profit margin | % | 40.0 | 39.0 | 32.7 | 33.2 | 33.9 | 35.7 | 32.6 | 40.9 | |
Effective tax rate | % | 27.9 | 26.0 | 29.5 | 27.0 | 26.9 | 26.2 | 17.6 | 25.5 | |
Net profit margin | % | 30.9 | 28.3 | 23.0 | 23.5 | 24.7 | 25.9 | 28.5 | 28.8 | |
Diluted EPS | Rs | 15.0 | 14.3 | 10.9 | 10.1 | 13.4 | 13.6 | 14.8 | 18.5 | |
Diluted EPS (TTM) | Rs | 43.3 | 49.2 | 50.2 | 50.2 | 48.7 | 48.0 | 51.9 | 60.3 | |
![]() |
Read: Divis Laboratories 1QFY21 Result Performance Review
More Pharmaceuticals Company Quarterly Results: ELDER PHARMA CIPLA AJANTA PHARMA INDOCO REMEDIES DISHMAN PHARMA
Compare DIVIS LABORATORIES With: ELDER PHARMA CIPLA AJANTA PHARMA INDOCO REMEDIES DISHMAN PHARMA
Compare DIVIS LABORATORIES With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
Indian share markets witnessed huge selling pressure today and failed to hold on to their opening gains as profit booking and weakness across all sectors erased gains.
For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.
For the quarter ended March 2020, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 35.4% YoY). Sales on the other hand came in at Rs 14 bn (up 9.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.
Here's an analysis of the annual report of DIVIS LABORATORIES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of DIVIS LABORATORIES. Also includes updates on the valuation of DIVIS LABORATORIES.
More Views on NewsIn this video, I'll show you why it might be the right time to take money of the table in pharma stocks.
The pandemic failed to thwart Richa's investing success formula for 2020.
The budget is just a few weeks away. Which stocks can you expect to move? Find out in this video.
Select smallcaps hold a great potential to become the multibaggers of tomorrow. Here's how you could get in early into these stocks.
More